Swiss reg revision could spell medtech uncertainty as scrutiny increases over customer discount, incentives
This article was originally published in Clinica
Executive Summary
Switzerland’s Therapeutic Products Act is currently being revised. In the wake of this regulatory overhaul, the medtech industry may soon be subject to a legal provision that prohibits companies from offering incentives and discounts to its customers, writes Philippe Fuchs*